Literature DB >> 21079577

MicroRNAs in breast cancer pathogenesis.

M Götte1.   

Abstract

Micro RNAs (miRNAs) are small non-coding RNAs which regulate fundamental cellular and developmental processes at the transcriptional and translational level. In breast cancer, expression of miRNAs is frequently dysregulated. Both tumor suppressor activity and oncogenic properties have been assigned to specific miRNAs, which modulate virtually all relevant stages of breast cancer progression, including tumor cell proliferation, apoptosis resistance, cancer cell migration, invasiveness and metastasis, tumor angiogenesis and cancer stem cell self-renewal. miRNA expression has been studied by microarray profiling, bead-based technologies and quantitative real-time PCR in archived formalin-fixed paraffin-embedded tumor specimens as well as blood and serum samples, allowing to identify specific miRNAs as novel diagnostic, prognostic and predictive markers. Moreover, the investigation of single nucleotide polymorphisms both in putative miRNA binding sites in the 3'UTRs of target genes, as well as in miRNA-endocing genes have revealed their diagnostic potential. In vitro experiments employing established breast cancer cell lines and in vivo xenograft studies have demonstrated the efficacy of oligonucleotide-based overexpression and inhibitor approaches of miRNA-targeted experimental therapies. Numerous studies have identified specific targets of miRNA action in breast cancer, including the established markers Her2/neu and ERalpha, TP53, and markers of angiogenesis. The future application of locked-nucleic acid miRNA inhibitors, and synergistic approaches involving conventional breast cancer therapeutics opens up promising new perspectives in breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079577

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  17 in total

1.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  MicroRNA-630 is a prognostic marker for patients with colorectal cancer.

Authors:  Dake Chu; Jianyong Zheng; Jipeng Li; Yunming Li; Jian Zhang; Qingchuan Zhao; Weizhong Wang; Gang Ji
Journal:  Tumour Biol       Date:  2014-07-01

Review 3.  MicroRNAs and STAT interplay.

Authors:  Gary Kohanbash; Hideho Okada
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 4.  Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis.

Authors:  Shichao Li; Xiaorong Yang; Jinmei Yang; Jiesheng Zhen; Dechun Zhang
Journal:  Clin Exp Med       Date:  2014-12-17       Impact factor: 3.984

5.  Integrated analysis of miRNA and mRNA during differentiation of human CD34+ cells delineates the regulatory roles of microRNA in hematopoiesis.

Authors:  Nalini Raghavachari; Poching Liu; Jennifer J Barb; Yanqin Yang; Richard Wang; Quang Tri Nguyen; Peter J Munson
Journal:  Exp Hematol       Date:  2013-10-16       Impact factor: 3.084

6.  Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells.

Authors:  Chao-Ming Hung; Wei-Chien Huang; Hsiao-Lin Pan; Pei-Hsuan Chien; Chih-Wen Lin; Lei-Chin Chen; Yu-Fong Chien; Ching-Chiao Lin; Kar-Hee Leow; Wen-Shu Chen; Jhen-Yu Chen; Chien-Yi Ho; Pao-Sheng Hou; Yun-Ju Chen
Journal:  Biomed Res Int       Date:  2014-02-27       Impact factor: 3.411

7.  The human miRNA repertoire of different blood compounds.

Authors:  Petra Leidinger; Christina Backes; Benjamin Meder; Eckart Meese; Andreas Keller
Journal:  BMC Genomics       Date:  2014-06-14       Impact factor: 3.969

8.  miRNAs can be generally associated with human pathologies as exemplified for miR-144.

Authors:  Andreas Keller; Petra Leidinger; Britta Vogel; Christina Backes; Abdou ElSharawy; Valentina Galata; Sabine C Mueller; Sabine Marquart; Michael G Schrauder; Reiner Strick; Andrea Bauer; Jörg Wischhusen; Markus Beier; Jochen Kohlhaas; Hugo A Katus; Jörg Hoheisel; Andre Franke; Benjamin Meder; Eckart Meese
Journal:  BMC Med       Date:  2014-12-03       Impact factor: 8.775

9.  MicroRNAs in Breastmilk and the Lactating Breast: Potential Immunoprotectors and Developmental Regulators for the Infant and the Mother.

Authors:  Mohammed Alsaweed; Peter E Hartmann; Donna T Geddes; Foteini Kakulas
Journal:  Int J Environ Res Public Health       Date:  2015-10-30       Impact factor: 3.390

10.  Blood born miRNAs signatures that can serve as disease specific biomarkers are not significantly affected by overall fitness and exercise.

Authors:  Christina Backes; Petra Leidinger; Andreas Keller; Martin Hart; Tim Meyer; Eckart Meese; Anne Hecksteden
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.